Table 2.
Effects on cardiovascular, metabolic and thermogenic variables of microinjection into the intermediolateral cell column at the fourth thoracic segment (T4 IML) of NMDA after ascorbic acid vehicle, or NMDA after five doses of 5-HT
| NMDA after 5-HT (pmol) | ||||||
|---|---|---|---|---|---|---|
| NMDA after vehicle | 20 pmol | 100 pmol | 200 pmol | 1000 pmol | 2000 pmol | |
| n | 7 | 5 | 5 | 9 | 5 | 15 |
| BAT temp. (°C) | +0.1 ± 0.0 | 0.0 ± 0.0 | +0.1 ± 0.1 | +0.1 ± 0.0 | +0.1 ± 0.0 | +0.1 ± 0.0 |
| Expired CO2 (%) | +0.2 ± 0.0 | +0.1 ± 0.0 | +0.0 ± 0.0 | +0.1 ± 0.0 | +0.0 ± 0.0 | +0.2 ± 0.0 |
| HR (beats min−1) | +79 ± 9 | +47 ± 13 | +34 ± 5 | +54 ± 10 | +49 ± 5 | +59 ± 9 |
| MAP(mmHg) | +10 ± 6 | +12 ± 8 | +3 ± 1 | +9 ± 4 | +2 ± 1 | +8 ± 2 |
Values are mean ±s.e.m. for peak changes from control values within 5 min of the microinjection of NMDA (12 pmol) into the right T4 IML (contralateral to the recorded BAT temperature). NMDA-evoked responses following microinjections of ascorbic acid or 5-HT did not differ from those evoked by NMDA only. Also the NMDA-evoked changes following 5-HT did not differ from those following ascorbic acid vehicle.